Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 14,851 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,851 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $6.47, for a total transaction of $96,085.97. Following the transaction, the chief technology officer now directly owns 146,049 shares in the company, valued at approximately $944,937.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Thursday, July 11th, Seshu Tyagarajan sold 13,330 shares of Candel Therapeutics stock. The shares were sold at an average price of $5.97, for a total value of $79,580.10.

Candel Therapeutics Stock Performance

Candel Therapeutics stock opened at $6.01 on Monday. The company has a market cap of $178.83 million, a price-to-earnings ratio of -4.70 and a beta of -0.95. Candel Therapeutics, Inc. has a 12 month low of $0.66 and a 12 month high of $14.30. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.00 and a quick ratio of 2.00. The stock’s 50-day moving average is $7.73 and its 200-day moving average is $4.74.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter. Equities analysts anticipate that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.